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Abstract The vav proto-oncogene product participates in the 
signaling pathways activated by various cell-surface receptors, 
including the type IIFN receptor. During engagement of the type 
I IFN receptor, p95va'' is phosphorylated on tyrosine residues, but 
the kinase regulating its phosphorylation has not been identified 
to date. Our studies demonstrate that p95v"'' forms a stable 
complex with the IFN-receptor-associated Tyk-2 kinase in vivo, 
and strongly suggest that this kinase regulates its phosphoryla-
tion on tyrosine. Thus, p95""1' is engaged in IFN-signaling by a 
direct interaction with the functional type I IFN receptor 
complex to transduce downstream signals. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Type I IFNs are pleiotropic cytokines that exert antiprolif-
erative, antiviral, and immunomodulatory activities [1,2] on 
normal and neoplastic cells. Several of the signaling events 
that occur during binding of IFNs to the type I IFN receptor 
(IFNR) have been now identified. IFNoc treatment of human 
cells induces tyrosine phosphorylation of the a and ß subunits 
of the type I IFNR [3,4], and activation of the receptor-asso-
ciated Tyk-2 and Jak-1 kinases (reviewed in [5]). Engagement 
of these kinases results in activation of the Stat- [5] and the 
IRS- [6,7] signaling pathways. The tyrosine phosphorylation 
of Stat- and IRS-proteins is a common event in the signaling 
pathways of all type I IFNs [4,6,7]. However, differences in 
the signaling pathways of different type I IFNs also exist, as 
demonstrated by the IFNß-specific interaction of the a and ßL 
subunits of the type I IFNR [4,8]. There is also evidence that 
the c-cbl proto-oncogene product is involved in type I IFN 
signaling, as suggested by its constitutive association with the 
Tyk-2 kinase, and its IFNa-dependent phosphorylation on 
tyrosine residues [9]. 
We have previously reported that the vav proto-oncogene 
product is also involved in type I IFN signaling, as evidenced 
by its rapid and transient tyrosine phosphorylation during 
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treatment of hematopoietic cells with IFNa, IFNß, and IFNco 
[10]. This protein is also phosphorylated during engagement 
of various cell surface receptors [11-19], suggesting its involve-
ment in diverse signaling cascades. In the present study we 
provide evidence that p95"°" associates with Tyk-2 in vivo, 
suggesting that Tyk-2 is the kinase that regulates its engage-
ment in IFNa signaling. 
2. Materials and methods 
2.1. Cells and reagents 
The U-266 and Daudi human cell lines were grown in RPMI 1640 
supplemented with 10% (v/v) fetal bovine serum (Life Technologies, 
Inc.) or 10% (v/v) denned calf serum (Hyclone Laboratories, Logan, 
UT) and antibiotics. Human recombinant IFNoc2 (IFNa) was pro-
vided by Hoffmann Laroche and Schering Plough. An antiphospho-
tyrosine monoclonal antibody (4G-10) was obtained from UBI (Lake 
Placid, NY). Polyclonal antibodies against Tyk-2 have been previ-
ously described [20,21]. The anti-p95"'"' polyclonal antibody was ob-
tained from Santa Cruz Biotechnology (Santa Cruz, CA). 
2.2. Immunoprecipitations and immunoblotting 
Cells were stimulated with IFNa for the indicated times. Cell lysis, 
immunoprecipitations, and immunoblotting using an enhanced chem-
iluminescence method were performed as previously described [10,22]. 
2.3. In vitro kinase assays and phosphoamino acid analysis 
These assays were performed essentially as described in previous 
reports [15,20]. 
3. Results and discussion 
We initially sought to determine whether IFNoc-dependent 
kinase activity can be detected in association with p95!"ro in in 
vitro kinase assays. U-266 myeloma cells were incubated at 
37°C in the presence or absence of IFNa, cell lysates were 
immunoprecipitated with an anti-p95""" antibody and the im-
munoprecipitates were subjected to an in vitro kinase assay. 
Some baseline kinase activity was detected in association with 
P95""", and after IFNa treatment increased significantly (Fig. 
1A). Interestingly, a 135 kDa protein which was phosphoryl-
ated in an IFNa-dependent manner, was also detectable in the 
anti-p95m" immunoprecipitates (Fig. 1A). Immunoblotting of 
the membrane with the anti-p95""" antibody confirmed that 
equal amounts of the p95"°" protein were present prior to and 
after IFNa treatment (Fig. IB). When the bands correspond-
ing to p95t,a" were excised and subjected to phosphoamino 
acid analysis, we noticed that after IFNa treatment there 
was induction of both serine and tyrosine phosphorylation, 
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Fig. 1. Detection of IFNa-dependent kinase activity in association with p95""". (A) U-266 cells were serum starved for 2 h and were subse-
quently treated with IFNa (104 U/ml) for 3 min at 37°C as indicated. Cells were lysed and cell lysates were immunoprecipitated with either 
non-immune rabbit immunoglobulin (RIgG) or an antibody against p95m" as indicated. Immunoprecipitates were subjected to an in vitro ki-
nase assay, analyzed by SDS-PAGE, and transferred to Immobilon membranes prior to autoradiography. (B) The membrane shown in A was 
immunoblotted with the anti-p95<*1" antibody to demonstrate that equal amounts of the protein were present prior to and after IFNa stimula-
tion. (C) Phosphoamino acid analysis of p95m" from the experiment shown in (A,B). 
suggesting that the protein associates with IFNa-dependent 
serine and tyrosine kinases (Fig. 1C). 
To determine the interaction of p951""' with other cellular 
proteins, we performed studies in which 35S-labeled Daudi 
cells were treated with IFNa, and cell lysates were immuno-
precipitated with the anti-p95"a" antibody. Proteins with ap-
proximate molecular masses of 190 (pl90), 135 (pl35), and 
70-80 (p80) kDa were detected in association with p95TOH' in 
these cells, prior to and after IFNa treatment (Fig. 2). These 
findings raised the possibility that p95mM' may be constitutively 
associated with a tyrosine kinase that regulates its phospho-
rylation in an IFNa-dependent manner. 
Among the proteins detected in association with p95"a" in 
the 35S-labeling and in vitro kinase assay experiments, there 
was a protein migrating at 135 kDa, which is similar to the 
molecular mass of the IFNa-dependent Tyk-2 kinase. We 
therefore sought to determine whether p95"a" interacts with 
Tyk-2. Daudi cells were incubated in the presence or absence 
of IFNa, and cell lysates were immunoprecipitated with anti-
bodies against p95"a" or Tyk-2 and immunoblotted with anti-
phosphotyrosine. For these studies a high number of cells was 
used, in order to immunoprecipitate a relatively large amount 
of the p95t*™ protein, and avoid missing detection of proteins 
interacting with it due to low stoichiometry of such associa-
Fig. 2. Association of p95"°" with cellular proteins in Daudi cells. 
35S-labeled Daudi cells were either not treated with IFNa (lanes 
3,6) or treated at 37°C with IFNa (2000 U/ml) for 5 min (lanes 2,5) 
or 30 min (lanes 1,4). Cells were lysed, and cell lysates were immu-
noprecipitated with either control normal rabbit immunoglobulin 
(RIgG) or an antibody against p95t""' as indicated. Immunoprecipi-
tates were analyzed by SDS-PAGE, and the gel was dried and sub-
jected to autoradiography. 
Fig. 3. p95vm is associated with the Tyk-2 protein tyrosine kinase. 
(A) Daudi cells (2.2 X 107/lane) were treated with IFNa for 5 min at 
37°C as indicated, cell lysates were immunoprecipitated with the in-
dicated antibodies, analyzed by SDS-PAGE and immunoblotted 
with antiphosphotyrosine. (B) Longer exposure of the blot shown in 
(A). (C) The blot shown in (A,B) was stripped and re-probed with 
an antibody against Tyk-2. 
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Fig. 4. Effect of kinase inhibitors on the IFNa-induced phosphoryl-
ation of p95m". (A) U-266 cells were incubated for 60 min at 37°C 
in the presence or absence of genistein (150 ug/ml) o r staurosporine 
(500 uM) as indicated. The cells were subsequently treated for 5 min 
with IFNa (104 U/ml) as indicated. Cell lysates were immunoprecip-
itated with an antibody against p95m", analyzed by SDS-PAGE and 
immunoblotted with antiphosphotyrosine. (B) U-266 cells that were 
either not incubated with kinase inhibitors, or incubated overnight 
with herbimycin A (1 uM), or incubated for 2 h with H-7 (50 uM) 
as indicated, were treated with IFNa (1000 U/ml) for 20 min at 
37°C. Cell lysates were immunoprecipitated with an anti-p95""1" anti-
body, analyzed by SDS-PAGE and immunoblotted with antiphos-
photyrosine. 
tions. Consistent with our previous findings [10], p95"a" ex-
hibited baseline tyrosine phosphorylation in these cells, but 
I F N a treatment further increased its phosphotyrosine content 
(Fig. 3A). After longer exposure of the same blot, we noticed 
that a tyrosyl-phosphoprotein that co-migrated with Tyk-2, 
was also detectable in the anti-p95"<n' immunoprecipitates 
(Fig. 3B). When the same blot was stripped and re-probed 
with an anti-Tyk-2 antibody, we found that Tyk-2 was present 
in anti-p95WK ' immunoprecipitates prior to and after I F N a 
stimulation (Fig. 3C). Thus, p95TO"' forms a stable complex 
with Tyk-2 in vivo, strongly suggesting that Tyk-2 is the ki-
nase that regulates its phosphorylation during I F N a stimula-
tion. 
We subsequently sought to determine the effect of tyrosine 
kinase inhibitors on the IFNa- induced tyrosine phosphoryla-
tion of p95mK ' . Cells were pre-incubated in the presence or 
absence of various kinase inhibitors, and were subsequently 
treated with I F N a . 
Fig. 4A shows that the IFNa-dependent tyrosine phospho-
rylation of p95!""' is inhibited in the presence of the specific 
tyrosine kinase inhibitor genistein and the non-specific kinase 
inhibitor staurosporine, which has been previously shown also 
to block IFNa-dependent phosphorylation of Stat-proteins 
[23]. Similarly, the IFNa- induced phosphorylation of p95"aB 
was partially inhibited when cells were treated in the presence 
of the specific tyrosine kinase inhibitor herbimycin A, but not 
in the presence of the protein kinase C inhibitor H-7 (Fig. 4B). 
Thus, the IFNa-dependent tyrosine phosphorylation of p95'M" 
is blocked in the presence of tyrosine kinase inhibitors, further 
suggesting that its phosphorylation is regulated by the asso-
ciated Tyk-2 tyrosine kinase. 
The vav proto-oncogene product participates in signaling 
cascades for various cytokines, growth factors, and hormones 
[11-19], and plays a critical role in embryogenesis [24] and T-
and B-cell function [25-27]. p95" t t" interacts with the ENX-1 
[28] and Ku-70 [29] proteins, as well as the heterogeneous 
nuclear ribonucleoprotein K [30,31] and a poly(rC)-specific 
RNA-binding protein [31], suggesting that it plays an impor-
tant role in the regulation of gene transcription and R N A 
biogenesis. The results of the present study provide evidence 
that p95"a" interacts with the functional type I I F N receptor 
complex, and strongly suggest that its engagement in I F N -
signaling is regulated by the Tyk-2 protein tyrosine kinase. 
Thus, in addition to Stats, p95"a" may provide an alternative 
direct link between the type I I F N receptor and nuclear events 
that regulate IFN-induced gene expression. 
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